ATE374200T1 - 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen - Google Patents

7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen

Info

Publication number
ATE374200T1
ATE374200T1 AT03709984T AT03709984T ATE374200T1 AT E374200 T1 ATE374200 T1 AT E374200T1 AT 03709984 T AT03709984 T AT 03709984T AT 03709984 T AT03709984 T AT 03709984T AT E374200 T1 ATE374200 T1 AT E374200T1
Authority
AT
Austria
Prior art keywords
jun
treatment
azaindole
neurodegenerative disorders
inhibitors
Prior art date
Application number
AT03709984T
Other languages
English (en)
Inventor
Piotr Graczyk
Hirotoshi Numata
Afzal Khan
Vanessa Palmer
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0207491A external-priority patent/GB0207491D0/en
Priority claimed from GB0217330A external-priority patent/GB0217330D0/en
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE374200T1 publication Critical patent/ATE374200T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
AT03709984T 2002-03-28 2003-03-17 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen ATE374200T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0207491A GB0207491D0 (en) 2002-03-28 2002-03-28 Inhibitors
GB0217330A GB0217330D0 (en) 2002-07-25 2002-07-25 Inhibitors

Publications (1)

Publication Number Publication Date
ATE374200T1 true ATE374200T1 (de) 2007-10-15

Family

ID=28676498

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03709984T ATE374200T1 (de) 2002-03-28 2003-03-17 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen

Country Status (11)

Country Link
US (1) US7534800B2 (de)
EP (1) EP1490364B1 (de)
JP (1) JP2005534618A (de)
KR (1) KR20040111445A (de)
CN (1) CN100368411C (de)
AT (1) ATE374200T1 (de)
AU (1) AU2003214412A1 (de)
CA (1) CA2480317A1 (de)
DE (1) DE60316542T2 (de)
IL (1) IL164187A0 (de)
WO (1) WO2003082868A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10037759A1 (de) * 2000-08-03 2002-07-04 Gruenenthal Gmbh Screeningverfahren
DE60316542T2 (de) 2002-03-28 2008-07-03 Eisai R&D Management Co., Ltd. 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
EP2295433A3 (de) 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. JNK Inhibitoren
US7612086B2 (en) * 2003-05-16 2009-11-03 Eisai R & D Management Co. Ltd. JNK inhibitors
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
GB0330042D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0405055D0 (en) * 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
BRPI0512330A (pt) * 2004-06-21 2008-02-26 Hoffmann La Roche derivados de pirazol-pirimidina
SE0401655D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
RU2389728C2 (ru) * 2004-07-27 2010-05-20 Сгкс Фармасьютиклз, Инк. Модуляторы киназы на основе производных пирролопиридина
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
WO2006015123A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CA2573573A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CN101027302B (zh) * 2004-07-27 2011-05-11 Sgx药物公司 吡咯并吡啶激酶调节剂
JP4953457B2 (ja) 2004-10-27 2012-06-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ プロゲステロン受容体モジュレーターとしてのピリジンイミダゾール及びアザ−インドール
FR2884821B1 (fr) * 2005-04-26 2007-07-06 Aventis Pharma Sa Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
US7846941B2 (en) 2005-05-17 2010-12-07 Plexxikon, Inc. Compounds modulating c-kit and c-fms activity and uses therefor
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
FR2887881B1 (fr) * 2005-07-01 2009-10-09 Pierre Fabre Medicament Sa Inhibiteurs de proteines kinases
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
WO2007067537A1 (en) * 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN101945877B (zh) 2008-02-25 2013-07-03 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
JP5368485B2 (ja) 2008-02-25 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー ピロロピラジンキナーゼインヒビター
CA2712507A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
ES2372908T3 (es) 2008-02-25 2012-01-27 F. Hoffmann-La Roche Ag Inhibidores de la pirrolopirazina quinasa.
WO2009106444A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
JP5370957B2 (ja) 2008-08-20 2013-12-18 学校法人日本大学 アポトーシス抑制剤
US8592448B2 (en) 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
CN106220623A (zh) 2009-11-06 2016-12-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8481541B2 (en) 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
EP2569315A1 (de) 2010-05-14 2013-03-20 OSI Pharmaceuticals, LLC Kondensierte bicyclische kinasehemmer
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
EP2571881A1 (de) 2010-05-20 2013-03-27 F.Hoffmann-La Roche Ag Pyrrolopyrazinderivate als syk- und jak-hemmer
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN105712992B (zh) * 2012-09-29 2018-10-26 上海科州药物研发有限公司 作为cMet抑制剂的化合物及其制备方法和用途
EP2738172A1 (de) * 2012-11-28 2014-06-04 Almirall, S.A. Neue bizyklische Verbindungen als CRAC-Kanalmodulatoren
US9206188B2 (en) * 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
US10155727B2 (en) 2014-08-15 2018-12-18 Janssen Pharmaceuticals, Inc. Pyrazoles
WO2016025917A1 (en) 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
AU2016291158B2 (en) 2015-07-09 2020-04-30 Janssen Pharmaceutica Nv Substituted 4-azaindoles and their use as GluN2B receptor modulators
US10071988B2 (en) 2016-02-10 2018-09-11 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
PL3558321T3 (pl) 2016-12-23 2023-10-23 Felicitex Therapeutics, Inc. Pochodne chinolin jako inhibitory kinaz dyrk1a i/lub dyrk1b
CN110402248B (zh) * 2017-03-15 2023-01-06 豪夫迈·罗氏有限公司 作为hpk1抑制剂的氮杂吲哚类
WO2019193516A2 (en) 2018-04-04 2019-10-10 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
CN114008052A (zh) 2019-06-14 2022-02-01 詹森药业有限公司 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途
BR112021025141A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b
CA3143103A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyridine carbamates and their use as glun2b receptor modulators
TW202112774A (zh) 2019-06-14 2021-04-01 比利時商健生藥品公司 經取代之吡唑并－吡啶醯胺及其作為ｇｌｕｎ２ｂ受體調節劑之用途
AU2020293642A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
MX2021015511A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de pirazina y sus usos como moduladores del receptor glun2b.
KR20220146458A (ko) * 2020-01-23 2022-11-01 마이오포르테 테라퓨틱스 인코포레이티드 Pgdh 억제제 및 그의 제조 및 사용 방법
CN114230565B (zh) * 2020-09-09 2023-10-27 成都奥睿药业有限公司 5-取代吲哚3-酰胺衍生物及其制备方法和用途
KR102347368B1 (ko) * 2020-11-03 2022-01-07 (주)케이메디켐 신규한 아자인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4719218A (en) * 1985-12-12 1988-01-12 Smithkline Beckman Corporation Pyrrolo[1,2-a]imidazole and pyrrolo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitor
HU207074B (en) 1990-12-07 1993-03-01 Richter Gedeon Vegyeszet Process for producing optically active cis and trans 14-(n-substituted-aminomethyl)-eburnane derivatives and pharmaceutical compositions comprising same
GB9026926D0 (en) 1990-12-12 1991-01-30 Smith Kline French Lab Novel process
SE9100920D0 (sv) 1991-03-27 1991-03-27 Astra Ab New active compounds
JP3119758B2 (ja) 1993-02-24 2000-12-25 日清製粉株式会社 ７−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
FR2732969B1 (fr) * 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1998047899A1 (en) 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
BR9812944A (pt) 1997-10-20 2000-08-08 Hoffmann La Roche Inibidores bicìclicos da cinase
WO1999051233A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO2000026211A1 (en) 1998-10-30 2000-05-11 Merck & Co., Inc. Thrombin inhibitors
EP1124823A1 (de) 1998-10-30 2001-08-22 Merck & Co., Inc. Thrombin inhibitoren
CN1136217C (zh) 1998-12-17 2004-01-28 霍夫曼-拉罗奇有限公司 作为jnk蛋白质激酶抑制剂的4-芳基羟吲哚
KR20010108024A (ko) 1998-12-17 2001-12-07 프리돌린 클라우스너, 롤란드 비. 보레르 단백질 키나제 억제제로서의 4,5-피라진옥신돌
US6265403B1 (en) 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
DE60041763D1 (de) 1999-04-23 2009-04-23 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
US6239132B1 (en) 1999-04-23 2001-05-29 Merck & Co., Inc. Thrombin inhibitors
KR20080028516A (ko) 1999-08-19 2008-03-31 시그널 파머슈티컬스 인크 Ｊｎｋ억제제로서의 피라졸로안트론과 그 유도체 및 이를함유하는 조성물
US6642375B2 (en) * 1999-12-07 2003-11-04 Fuji Photo Film Co., Ltd. Fluorescent substances
WO2001047922A2 (en) * 1999-12-24 2001-07-05 Aventis Pharma Limited Azaindoles
DE60132975T2 (de) 2000-01-06 2009-02-26 Merck Frosst Canada Inc., Kirkland Neue substanzen und verbindungen als protease-inhibitoren
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0108770D0 (en) * 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003082869A1 (en) 2002-03-28 2003-10-09 Eisai Co., Ltd. Azaindoles as inhibitors of c-jun n-terminal kinases
DE60316542T2 (de) 2002-03-28 2008-07-03 Eisai R&D Management Co., Ltd. 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen
US20030235042A1 (en) * 2002-06-24 2003-12-25 Harris Jeffrey M. Carrier card and method
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
GB0305142D0 (en) * 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
EP2295433A3 (de) * 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. JNK Inhibitoren
US7612086B2 (en) * 2003-05-16 2009-11-03 Eisai R & D Management Co. Ltd. JNK inhibitors
GB0516156D0 (en) * 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors

Also Published As

Publication number Publication date
JP2005534618A (ja) 2005-11-17
US20050272761A1 (en) 2005-12-08
EP1490364A1 (de) 2004-12-29
CA2480317A1 (en) 2003-10-09
CN100368411C (zh) 2008-02-13
WO2003082868A1 (en) 2003-10-09
AU2003214412A1 (en) 2003-10-13
CN1656094A (zh) 2005-08-17
EP1490364B1 (de) 2007-09-26
KR20040111445A (ko) 2004-12-31
DE60316542T2 (de) 2008-07-03
US7534800B2 (en) 2009-05-19
IL164187A0 (en) 2005-12-18
DE60316542D1 (de) 2007-11-08

Similar Documents

Publication Publication Date Title
ATE374200T1 (de) 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen
DE60331219D1 (de) Azaindole als hemmstoffe von c-jun n-terminalen kinasen
ATE297394T1 (de) Jun kinase inhibitoren
WO2004078756A3 (en) Jnk inhibitors
GB0516156D0 (en) JNK inhibitors
GB0405055D0 (en) JNK inhibitors
WO2004101565A3 (en) Jnk inhibitors
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
PT1660507E (pt) Inibidores de proteassoma e seus métodos de utilização
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
EP1608627A4 (de) Bicyclische anilidspirohydantoine als cgrp-rezeptorantagonisten
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
MXPA05009535A (es) Compuestos de acido n - alquil - hidroxamico - isoindolilo y sus usos farmaceuticos.
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
MXPA05008438A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6.
DE60220385D1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
TW200724140A (en) Hydantoin compounds
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
DE60326069D1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
ATE443044T1 (de) Tace inhibitoren
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
GB0407025D0 (en) Novel compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties